NCT05517837View on ClinicalTrials.gov

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions
Healthy Participants
Interventions
DRUG

BMS-986421

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (1)

90630

Local Institution - 0001, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05517837 - A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants | Biotech Hunter | Biotech Hunter